Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring

European Journal of Cancer Prevention

Volumn 22, Issue 2, 2013, Pages 121-125

  Gilbert, Rebecca ^a   Metcalfe, Chris ^a   Fraser, William D ^b   Lewis, Sarah ^a   Donovan, Jenny ^a   Hamdy, Freddie ^c   Neal, David E ^d   Lane, J Athene ^a   Martin, Richard M ^a   Tilling, Kate ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

1,25 dihydroxyvitamin D; 25 hydroxyvitamin D; progression; prostate cancer; prostate specific antigen; vitamin D; vitamin D pathwaygenes

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; PROSTATE SPECIFIC ANTIGEN; VITAMIN D;

ADULT; AGED; ARTICLE; CANCER RISK; DISEASE COURSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN BLOOD LEVEL;

AGED; COHORT STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VITAMIN D;

EID: 84873405368     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3283584954     Document Type: Article

References (10)

1. Chen L, Davey Smith G, Evans DM, Cox A, Lawlor DA, Donovan J, et al. (2009).Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: Findings from the prostate testing for cancerand treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev 18:2874-2881.
2. D'Amico AV, Chen MH, Roehl KA, Catalona WJ (2004). Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135.
3. Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, et al. (2011). Prediagnostic plasma vitamin d metabolites and mortality among patientswith prostate cancer. PLoS One 6:e18625.
4. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy FC, Neal DE, et al. (2012). Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer 131:1187-1196.
5. Gross C, Stamey T, Hancock S, Feldman D (1998). Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035-2039.
6. Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA, et al. (2010). Vitamin D pathway gene variants and prostate cancer prognosis.Prostate 70:1448-1460.
7. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL (2010). Latest results from the UK trials evaluating prostate cancer screening and treatment: He CAP and ProtecT studies. Eur J Cancer 46:3095-3101.
8. National Institute of Health (2011). State-of-the-Science Conference Statement, Role of Active Surveillance in the Management of Men with Localized Prostate Cancer
9. Tilling K, Garmo H, Metcalfe C, Holmberg L, Hamdy FC, Neal DE, et al. (2010). Development of a new method for monitoring prostate-specific antigenchanges in men with localised prostate cancer: A comparison of observationalcohorts. Eur Urol 57:446-452.
10. Van den Bergh RC, Roemeling S, Roobol MJ, Wolters T, Schrö der FH, Bangma CH (2008). Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer -a review. Eur Urol 54:505-516.